{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:45:08Z","timestamp":1782747908709,"version":"3.54.5"},"reference-count":9,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Pathogenesis and Therapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.cpt.2026.01.002","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:20:10Z","timestamp":1769041210000},"page":"321-325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low-dose decitabine increases peripheral natural killer T (NKT)-like cell proportions in patients with chronic myeloid neoplasms"],"prefix":"10.1016","volume":"4","author":[{"given":"Zhanqiang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhili","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuechun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpt.2026.01.002_bib1","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1200\/JCO.19.03277","article-title":"Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: an open-label, multicenter, randomized controlled trial","volume":"38","author":"Gao","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpt.2026.01.002_bib2","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.3390\/cancers14143352","article-title":"Lymphocyte exhaustion in AML patients and impacts of HMA\/venetoclax or intensive chemotherapy on their biology","volume":"14","author":"Zhigarev","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.cpt.2026.01.002_bib3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1182\/blood-2017-06-790204","article-title":"Decitabine enhances targeting of AML cells by CD34(+) progenitor-derived NK cells in NOD\/SCID\/IL2Rg(null) mice","volume":"131","author":"Cany","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.cpt.2026.01.002_bib4","doi-asserted-by":"crossref","first-page":"1137175","DOI":"10.3389\/fonc.2023.1137175","article-title":"Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT","volume":"13","author":"Chen","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.cpt.2026.01.002_bib5","doi-asserted-by":"crossref","first-page":"755662","DOI":"10.3389\/fphar.2021.755662","article-title":"Concentration-dependent decitabine effects on primary NK cells viability, phenotype, and function in the absence of obvious NK cells proliferation-original article","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cpt.2026.01.002_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e25254","article-title":"Unveiling the role of NK cells, NKT-like cells, and \u03b3\u03b4 cells in pathogenesis of type 1 reactions in leprosy","volume":"10","author":"Pathak","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.cpt.2026.01.002_bib7","doi-asserted-by":"crossref","first-page":"1173375","DOI":"10.3389\/fimmu.2023.1173375","article-title":"Novel lipid antigens for NKT cells in cancer","volume":"14","author":"Lee","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.cpt.2026.01.002_bib8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.cpt.2023.11.002","article-title":"Co-culture models for investigating cellular crosstalk in the glioma microenvironment","volume":"2","author":"Niu","year":"2024","journal-title":"Cancer Pathog Ther"},{"key":"10.1016\/j.cpt.2026.01.002_bib9","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1016\/j.cell.2023.05.028","article-title":"DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCs","volume":"186","author":"Guo","year":"2023","journal-title":"Cell"}],"container-title":["Cancer Pathogenesis and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949713226000029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949713226000029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:57:58Z","timestamp":1782745078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949713226000029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2949713226000029"],"URL":"https:\/\/doi.org\/10.1016\/j.cpt.2026.01.002","relation":{},"ISSN":["2949-7132"],"issn-type":[{"value":"2949-7132","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose decitabine increases peripheral natural killer T (NKT)-like cell proportions in patients with chronic myeloid neoplasms","name":"articletitle","label":"Article Title"},{"value":"Cancer Pathogenesis and Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpt.2026.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Chinese Medical Association (CMA).","name":"copyright","label":"Copyright"}]}}